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As surgical and catheter interventions advance, patients with congenital heart disease 
are now offered alternative treatment options that cater to their individual needs. 
Furthermore, collaboration between interventional cardiologists and cardiac surgeons 
have led to the development of hybrid procedures, using the best techniques of each 
respective field to treat these complex cardiac entities from initial treatment in the pedi-
atric patient to repeat intervention in the adult. We present a review of the increased 
popularity and trend in hybrid procedures in congenital heart disease without the use of 
cardiopulmonary bypass.
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COMMON AND POPULAR HYBRiD PROCeDUReS
 1. Hybrid Stage I palliation for hypoplastic left heart syndrome (HLHS).
 2. Perventricular ventricular septal defect (VSD) closure; muscular and perimembranous.
 3. Perventricular pulmonary valve implantation.
 4. Hybrid pulmonary valvuloplasty for pulmonary atresia.
 5. Hybrid aortic valvuloplasty.
 6. Hybrid stent placement in the branch pulmonary arteries.
 7. Per-atrial atrial septal defect closure.
 8. Hybrid paravalvar leak closure of the mitral valve.
 9. Hybrid paravalvar leak closure of the aortic valve.
10. Hybrid procedures for stent placement in pulmonary vein for recurrent venous stenosis.
11. Hybrid stent placement in coarctation of aorta.
A detailed description of all the above procedures cannot be addressed in this manuscript. We 
will, however, address what we believe are the most common of the above procedures and some that 
may become more popular in the near future.
HYBRiD STAGe i PALLiATiON iN HLHS
Patients with a “single ventricle,” whether defined anatomically or physiologically, are some of the 
most complex of patients. HLHS can consist of a variety of left heart anatomical combinations that 
lead to left ventricular and aortic underdevelopment. Traditionally, a surgical staged palliation 
is performed with Norwood procedure, followed by a bidirectional cavopulmonary anastomosis 
(bidirectional Glenn), and Fontan. However, in infants with multiple comorbidities and low birth 
weight, restrictions and high risks are involved with cardiopulmonary bypass (1, 2). For these rea-
sons, a hybrid palliation procedure that can circumvent cardiopulmonary bypass and its associated 
complications appeared more attractive.
FiGURe 1 | Hybrid stage i palliation: angiography of branch pulmonary arteries after bilateral pulmonary artery banding in a right anterior oblique 
view (A) and left anterior oblique view (B). Fluoroscopic image of stent implantation within the patent ductus arteriosus (C).
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Technique
In 1993, the first reported hybrid stage I approach in HLHS was 
described by Gibbs et al. where through a median sternotomy the 
branch pulmonary arteries were banded, and the patent ductus 
arteriosus (PDA) was percutaneously stented (3). The technique 
was later revised in 2002 by Akintuerk et al. (4) and later adopted 
by Galantowicz et al. (5) and Bacha et al. (1), where the procedure 
has continued to be refined with a steep learning curve.
The primary goals and procedural steps as described by 
Galantowicz and Cheatham are (6)
 1. unobstructed systemic output via the ductus arteriosus,
 2. balance of the pulmonary and systemic circuits, and
 3. unobstructed flow via the atrial septum.
The patient is placed under general anesthesia, and a median 
sternotomy is performed. The branch pulmonary arteries are 
banded to a degree suitable by follow-up angiography and pres-
sure measurements (Figures  1A,B). This step is done first to 
optimize cardiovascular hemodynamics in both the pulmonary 
and systemic circuits. Following this step, the main pulmonary 
artery (MPA) is directly punctured and a sheath is placed for stent 
delivery within the PDA (Figure 1C).
The atrial septum is addressed at a subsequent date by stand-
ard percutaneous balloon atrial septostomy, if needed, and is 
usually performed 1–2 weeks after the hybrid procedure when 
the neonate is hemodynamically stable (6).
The hybrid approach thus allows for palliation without 
cardiopulmonary bypass or cardiac hypothermia and therefore 
allows time for neonatal growth prior to the second stage. The 
comprehensive stage II repair is performed around 6 months of 
age, it is more extensive and involves PDA stent removal, aortic 
arch reconstruction, branch pulmonary artery de-banding with 
revision of the branch pulmonary arteries, along with a bidirec-
tional cavopulmonary anastomosis (5, 6).
Patient Selection and Outcomes
The goal of staged single ventricle palliation is to normalize 
the systemic ventricle volume and pressure load and maintain 
unobstructed cardiac output with adequate oxygen saturated 
blood, while also protecting the pulmonary vascular bed for 
subsequent palliations. Neonates present a particular challenge 
as their pulmonary vascular resistance is elevated early in life, 
requiring a staged approach to control pulmonary blood flow and 
allow development of the vascular bed (7). Furthermore, infants 
with low birth weight, prematurity, and coexisting comorbidities 
add increased complexity and challenges.
The optimal patient for utilization of the hybrid stage I 
approach has not been clearly defined as of yet. However, in a 
study by Karamlou et al., pediatric centers with high use of the 
hybrid stage I palliation were those that had greater mortality 
rates after the traditional Norwood procedure (8). Additionally, 
in that study, patients in whom the hybrid palliation was per-
formed were indeed higher risk patients. High-risk patients are 
defined as infants with low birth weight <2.5  kg, prematurity, 
ventricular dysfunction, severely hypoplastic ascending aorta 
(<2 mm), genetic malformations, and severe non-cardiac comor-
bidities, which have been found to have as high as 60% mortality 
risk rates after the Norwood procedure (1, 2, 9–11). Therefore, 
those neonates with complex medical comorbidities or those 
traditionally found to have increased risk with associated initial 
surgical palliation have been proposed as a population set where 
the hybrid approach could be considered.
In patient populations with increased risk factors, there have 
been studies demonstrating the hybrid approach as a valuable 
alternative. Venugopal et al. reported 14 of 21 patients surviving 
the initial procedure, to later go on to comprehensive stage II 
palliation (2). Bacha et  al. reported a 78.5% hospital survival 
rate after the initial hybrid palliation with 8 of their initial 14 
high-risk patients undergoing stage II repair (1). Furthermore, 
when compared to the Norwood procedure, there are similar 
results to survival after Fontan completion with overall survival 
of approximately 80% (5, 12, 13). Alternatively, the approach 
has also been shown to be a beneficial tactic in biventricular 
repair for patients with borderline small left heart structures 
(14). Therefore, these studies demonstrate that both the 
traditional surgical approach and the hybrid approach have 
shown to provide adequate physiology for Fontan completion 
in single ventricle palliation. However, of note are the techni-
cal considerations with the hybrid procedure. There has been 
reported need for increased pulmonary artery re-intervention, 
ductal stent re-intervention, or the development of preductal 
FiGURe 2 | Hybrid muscular ventricular septal defect closure. 
Schematic diagram illustrating the steps involved in deployment of the device 
through the right ventricular free wall. RV, right ventricle; LV, left ventricle; 
MPA, main pulmonary artery; Ao, aorta; SVC, superior vena cava; TV, 
tricuspid valve; RA, right atrium; IVC, inferior vena cava. Reprinted with 
permission from publisher: Elsevier (24).
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retrograde coarctation (1, 5, 12, 15–17). Nevertheless, as 
experience expands, and the technique continues to be refined, 
this approach may offer a replaced standard for those complex 
infants where increased surgical jeopardy is a concern.
HYBRiD vSD CLOSURe
The ventricular septum is highly complex and consists of an 
inflow, trabecular/apical, and outflow region; it has two separate 
tissue characteristics: a muscular and membranous portion, and 
is surrounded by the different morphological structures of the 
right ventricles (RVs) and the left ventricles (LVs). Muscular 
VSDs can be described as central, apical, anterior, or posterior. 
VSDs can be malaligned, committed to one or both outflow 
tracts, and can exist as an isolated defect, multiple defects, and/or 
associated with other congenital cardiac lesions (18–20).
Traditionally, large muscular and perimembranous ventricu-
lar defects were closed via patch repair with surgery requiring 
cardiopulmonary bypass, with closure at times challenging due 
to location and periodically resulting in residual defects (21). The 
percutaneous approach with device closure was first described 
in 1988 (22), and with refinement over the years, has provided 
benefit in suitable cases. However, the percutaneous approach is 
also technically challenging, as limitation in catheter manipula-
tion in small babies prevents closure of complicated defects. 
Additionally, the delivery sheath and its sizes are never too soft for 
smaller babies. This increases the risks of vascular injury, as well 
as possible adverse events such as hemodynamic compromise 
and arrhythmias (23).
With the goal to avoid the risks associated with prolonged 
cardiopulmonary bypass, the first perventricular closure of a 
muscular VSD was performed in a baby by Amin et al. in 1998 
(24), followed by perventricular closure by Amin et al. in 2004 
of a perimembranous VSD (25). Since then, the hybrid approach 
has been shown to be an acceptable alternative, with minimal 
incision, relatively straight access to the defect, avoidance of 
cardiopulmonary bypass during VSD closure, and the potential 
to both small and large patients without the risk of hemodynamic 
compromise.
Technique
For the hybrid approach, transesophageal (TEE), or occasionally 
epicardial, echocardiography is performed to assess the defect, 
guide during device placement, and assess after device release. 
There have been descriptions of the perventricular or per-atrial 
approach through a median sternotomy, a modified partial 
median sternotomy, or a left anterior parasternal incision at the 
third intercostal space (in cases of supracristal VSDs) (26).
During this technique, the RV free wall is exposed, and the 
puncture site is determined by pressing on the RV free wall 
while assessing by TEE, to ensure the site is as perpendicular 
to the VSD as possible. Then, purse string or pledgetted mat-
tress sutures are placed around the puncture site, and a wire is 
introduced via the angiocatheter across the VSD, and the wire is 
exchanged for the delivery sheath, with or without serial dilation. 
The device of choice is loaded under echocardiography, the left 
disk is deployed, and while retracting the sheath slowly, the waist 
is deployed within the defect itself, followed by deployment of 
the right disk within the RV (Figure 2). Prior to release, thor-
ough evaluation with echocardiography is performed to ensure 
proper placement and no residual defects (Figure 3). The device 
is released followed by sheath removal, and the purse string 
sutures are tied to close the RV puncture site. The chest is closed 
in routine fashion.
Devices
There have been various devices developed and used for the 
closure of VSDs with some out of fashion and some still on the 
bench for experimentation. Presently, the most popular devices 
used are the Amplatzer VSD Occluders (AGA Medical, Plymouth, 
MN, USA) (27–29). Off label use of Amplatzer duct occluders is 
also relatively common (30). Initial and midterm studies show 
promising results (31).
Use in Different vSD Types
The indications for perventricular perimembranous VSD closure 
are generally the same as the surgical indications. Of note, per-
imembranous VSDs pose a challenge to any type of repair, given 
their location adjacent to the aortic valve, mitral and tricuspid 
valves (TVs), and electrophysiological circuit. In a review by Yin 
et al., of the reported cases from 2008 to 2013, the perventricular 
complete closure success rate was 77–100%, and higher than that 
of muscular VSDs (26). Additionally, the incidence of complete 
heart block was lower than the percutaneous approach, 0.6 versus 
FiGURe 3 | Transesophageal echocardiographic images of steps involved in perventricular ventricular septal defect (vSD) closure. (A,B) 4-chamber 
view without (A) and with (B) color Doppler showing the mid muscular VSD. (C) Wire through the right ventricular free wall and across the defect. (D) Delivery sheath 
in the left ventricle (LV) cavity. (e) Left disk deployed in the LV. (F) Left disk aligned with the ventricular septum. (G) Device waist and part of the right disk have been 
deployed. (H) Complete deployment of the right disk with optimal device position. Reprinted with permission from publisher: John Wiley and Sons (29).
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2%, respectively (31). Another possible complication reported is 
valve regurgitation, with device-induced tricuspid regurgitation 
being the most common, followed by aortic valve regurgitation, 
most resolving or asymptomatic at follow-up (31).
Muscular VSDs are the second most common subtype of VSDs 
(19). Apical and anterior muscular VSDs can be difficult to access 
via a surgical trans-atrial approach and the right ventriculotomy 
approach due to limited view through the RV trabeculations. 
Additionally, left ventriculotomy has been associated with ven-
tricular dysfunction, arrhythmia, and aneurysms (32). In a recent 
review of reported studies from 2003 to 2013, the reported suc-
cess rate of perventricular device complete closure of muscular 
VSDs is 50–100% with no reported case of RV dysfunction, lower 
rates of arrhythmias when compared to surgical closure, and 80% 
closure rate at midterm follow-up (though the review admits to 
limitations with small study sizes in the reports) (26). In a long-
term follow-up by Kang et al., at a median time of 6.5 years post 
device implantation, of 10 patients who underwent the technique, 
5 had complete closure, and 4 patients had residual hemodynami-
cally insignificant defects. One patient had TV entrapment from 
the device and underwent surgical removal and repair (33). 
Therefore, as longer term results are generated, the benefit of 
perventricular muscular VSDs can be further evaluated and may 
provide an acceptable alternative to surgical repair.
HYBRiD PULMONARY vALve 
iNTeRveNTiONS
Right ventricular outflow tract (RVOT) structural and congenital 
heart disease with obstruction in the form of pulmonary valve 
stenosis or atresia have previously been treated surgically with 
transannular patch repair/RVOT conduit or valvotomy, or 
percutaneously with transcatheter pulmonary valve/RVOT stent 
or balloon valvuloplasty. The palliations lead to either restenosis 
or pulmonary regurgitation; this may lead to RV hypertrophy or 
dilation, further progressing to ventricular dysfunction and 
FiGURe 4 | Right ventricle (Rv) angiogram. Angiographic catheter 
advanced antegrade via femoral sheath and into RV and demonstrates 
Melody valve in proper position.
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arrhythmias. There is no consensus regarding the timing of 
pulmonary valve replacement (34). However, in patients where 
weight, complex comorbidities, vascular access, venous occlu-
sion, previous multiple sternotomies, or risk of cardiopulmonary 
bypass are limitations and pose increased risk for complication, 
there are new and innovative hybrid approaches that have been 
developed. And, in this anatomical scenario, the hybrid proce-
dure allows for intervention in a range of patients, from pediatric 
to adult.
Perventricular Transcatheter 
Pulmonary valves
Transcatheter pulmonary valve replacements have been steadily 
increasing since the first transcatheter pulmonary valve replace-
ment in 2000 (35, 36). Since then, there are new innovations in 
the development and use of transcatheter pulmonary valves. Yet, 
presently, there are two common transcatheter pulmonary valves 
being used in the USA as described by a recent review (35). The 
Melody valve (Medtronic, Minneapolis, MN, USA) is a bovine 
jugular venous valve that is available in the following diameters: 
18, 20, and 22 mm. The Edwards Sapien (Edwards Lifesciences 
LLC, Irvine, CA, USA) valve was originally conceived for aortic 
valve replacement but was then successfully used in the pulmo-
nary position (37). This is a bovine pericardial valve mounted 
within a stainless steel stent, with diameters of 23 and 26 mm. 
The offspring of the Edwards Sapien valve is the newly developed 
and FDA-approved Sapien XT (Edwards Lifesciences LLC, Irvine, 
CA, USA) with diameters of 23, 26, and 29 mm, but only requir-
ing an 18-19-Fr introducer.
The inclusion criteria for percutaneous transcatheter pulmo-
nary valve placement were patients >30 kg and >5 years of age, 
likely to reduce the risk of vascular injury due to the large size of 
the 22-Fr delivery sheath for Melody valve placement (38, 39). 
However, recently Berman et al. (40) reported 25 patients, median 
weight 21.4 kg, where percutaneous Melody valve placement was 
successful in 23 patients. However, there still lies the risk in the 
population subset where venous access size or occlusion poses an 
issue to traditional percutaneous sheath placement.
The hybrid pulmonary valve approach was first described 
as a bailout technique following failed percutaneous delivery 
in patients at risk for cardiopulmonary bypass. Simpson et  al., 
Berman et al., and Cubeddu and Hijazi described the technique as 
a bailout approach in larger patients, ages 13, 16, and 44 years with 
both the Melody and Edwards Sapien valve (41–43). In these case 
reports, the transcatheter valve could not be successfully placed 
percutaneously, due to angle, malposition, or embolization into 
the RVOT. Therefore, after successful surgical removal of the 
failed valve, transcatheter pulmonary valves were placed via the 
perventricular approach. The hybrid technique was subsequently 
performed electively in a 12-kg patient (44).
Technique
Prior to the hybrid procedure, a routine diagnostic catheteriza-
tion is performed via the traditional femoral approach with 
angiography of the RVOT, MPA, and branch pulmonary arteries. 
Coronary artery compression testing with balloon inflation of the 
RVOT must be done either during the diagnostic catheterization 
or during the hybrid procedure, prior to transcatheter valve 
placement, to ensure safe distance of the coronaries.
The base of the RV is accessed by a subxiphoid incision. This 
is followed by direct perventricular access through the RV ini-
tially with an angiocatheter, followed by sheath placement in the 
RVOT. Following sheath placement, a stiff wire, either a Amplatz 
Superstiff (Cordis, Johnson & Johnson, USA) or Lunderquist 
(Cook Medical, Bloomington, IN, USA), is secured in a distal 
branch pulmonary artery, and the RVOT is stented followed by 
transcatheter pulmonary valve placement. Once the valve has 
been deployed, follow-up angiography can be performed to con-
firm placement (Figure 4). Lastly, the sheath is removed, and the 
purse string suture is tied to close the RV, followed by subxiphoid 
incision closure (Figure 5).
Potential Complications
This technique for pulmonary valve placement is feasible and 
with continued refinement and development can provide benefit 
to a range of patients with increased risk factors. There have been 
no post procedural complications reported. However, intra-
procedural risk is present. In a recent case series by Gupta et al. 
(45), five patients with a mean weight 16.2 kg (range 4.7–28.1 kg) 
were treated with elective perventricular Melody valve placement 
via the subxiphoid approach. Technical success in this series was 
100%. However, in two patients with absent pulmonary valve 
diagnoses, the stent migrated during advancement of the delivery 
sheath, requiring anchoring in the distal main or branch pulmo-
nary artery, but without sequela. TV chordal injury also occurred 
in one patient, where TEE was not utilized. Therefore, this series 
demonstrates that the technique is feasible even in small-sized 
patients but with a need to minimize complications. First, the 
stent should be deployed during the same procedure, if possible, 
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but if preexisting stenting has been performed, sheath advance-
ment can be difficult and increases the risk of stent embolization. 
Hence, careful advancement of the delivery sheath is crucial, with 
proper securement of the wire. Additionally, the use of TEE can 
help to avoid TV entrapment during initial sheath advancement 
in the RVOT. Overall, the technique has an ongoing learning 
curve and with continued improvement may provide benefit to 
patients, young and old.
Tetralogy of Fallot with Transannular 
Repair
The hybrid pulmonary valve replacement has also been trialed in 
previous anatomical scenarios once thought to be contraindica-
tions for transcatheter approach. In many patients with Tetralogy 
of Fallot, the initial surgical repair is performed with a transan-
nular patch. Pulmonary regurgitation develops and chronically 
can leads to RV dysfunction, exercise intolerance, and cardiac 
arrhythmias (35). To address this, these patients eventually require 
pulmonary valve replacement. However, the complexity in this 
patient subset arises due to the chronic dilation of the RVOT, 
which leads to an unpredictable landing zone for transcatheter 
pulmonary valve placement. The percutaneous approach in these 
patients is difficult to perform but has been successfully reported 
by reducing the diameter of the RVOT either with implanting 
multiple stents (“Russian Doll Technique”) or overlapping stents 
in the branch pulmonary arteries and then implanting the valve 
(46–48). Yet, the problem still evades a strict percutaneous 
approach when the RVOT remains too large.
The hybrid approach allows an alternative strategy for manip-
ulating the RVOT and MPA, prior to transcatheter pulmonary 
valve placement, and still avoids cardiopulmonary bypass (49). 
In a case in a 17-year-old male, through a midline sternotomy, a 
polytetrafluoroethylene graft (Gore-Tex, WL Gore & Associates 
Inc., Flagstaff, AZ, USA) was wrapped around the MPA to restrict 
the diameter to 22 mm (50). Following MPA restriction, a Melody 
valve was delivered through the perventricular approach over a 
24-mm BIB balloon (NuMed Inc., Hopkinton, NY, USA). In an 
another recent study, MPA plication using longitudinal running 
sutures or mattress sutures was done to reduce the RVOT to 
22–24 mm, followed by successful perventricular melody valve 
placement in three patients (51). Furthermore, 3D imaging 
modalities followed by use of hybrid strategy to place valves has 
been described (52).
Pulmonary Atresia
In neonates with pulmonary atresia and anatomy favorable 
to biventricular repair, the initial intervention is focused on 
decompression of the RV and RVOT by creating either a surgi-
cal valvotomy or via transcatheter perforation and balloon 
valvuloplasty with or without stenting (53, 54). Several recent 
studies have demonstrated safety and feasibility of direct hybrid 
approach to perforate pulmonary valve (53–55).
HYBRiD AORTiC BALLOON 
vALvULOPLASTY
Congenital aortic stenosis in the neonate can present as an iso-
lated lesion resulting in LV hypertrophy, and more significantly, 
severe systemic outflow obstruction, which can subsequently 
lead to sudden cardiac death (56). These patients often require 
multiple re-interventions throughout life due to their dysplastic 
aortic valve. To avoid initial open surgery in low weight infants, 
percutaneous balloon valvuloplasty was developed and does 
have respectable results but can be difficult in a low birth weight 
infant for several reasons (57–59). A hybrid technique to access 
the aortic valve directly through the ascending aorta has been 
described (60).
Technique
In a recent study, this procedure was performed in 18 patients 
(mean weight: 4.6 ±  0.8  kg) (60). Patients were placed under 
general anesthesia, and a median sternotomy was performed with 
a purse string suture placed in the ascending aorta, and a wire was 
advanced and placed in the LV. An appropriate sized balloon was 
FiGURe 5 | Subxiphoid access for perventricular Melody valve implantation. (A) The size and location of the surgical incision. (B) The 22-Fr Melody valve delivery 
sheath being inserted through the incision. (C) Final appearance of the chest wall after closure. Reprinted with permission from publisher: John Wiley and Sons (44).
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